Kennedy Capital Management’s Verona Pharma VRNA Stock Holding History

Kennedy Capital Management’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-98,378	Closed	-$10.5M	–	587
2025 Q3	$10.5M	Sell	98,378 -10,672	-10%	-$1.11M	0.23%	147
2025 Q2	$10.3M	Sell	109,050 -27,498	-20%	-$2.04M	0.25%	133
2025 Q1	$8.67M	Sell	136,548 -209,555	-61%	-$12.5M	0.21%	168
2024 Q4	$16.1M	Sell	346,103 -12,344	-3%	-$463K	0.36%	57
2024 Q3	$10.3M	Buy	358,447 +20,912	+6%	+$515K	0.23%	135
2024 Q2	$4.88M	Buy	337,535 +214,320	+174%	+$3.13M	0.1%	323
2024 Q1	$1.98M	Sell	123,215 -42,442	-26%	-$734K	0.04%	523
2023 Q4	$3.29M	Buy	165,657 +26,056	+19%	+$385K	0.07%	387
2023 Q3	$2.28M	Buy	139,601 +22,529	+19%	+$434K	0.06%	436
2023 Q2	$2.47M	Buy	+117,072	New	+$2.5M	0.06%	420

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Kennedy Capital Management's VRNA Position: Q4 2025 in Review

Kennedy Capital Management sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 98,378 shares — an estimated $10.5M sold.

Kennedy Capital Management first reported a position in VRNA in Q2 2023 and held it in 10 quarters. The position peaked at $16.1M in Q4 2024. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Kennedy Capital Management reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Kennedy Capital Management sold 98,378 Verona Pharma shares in Q4 2025, an estimated $10.5M.
Kennedy Capital Management first reported a position in Verona Pharma in Q2 2023 and held it in 10 quarters.
Kennedy Capital Management's Verona Pharma position peaked at $16.1M in Q4 2024.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Kennedy Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.